CY1113616T1 - Υγρη συνταγοποιηση που περιεχει υψηλη συγκεντρωση αντισωματος - Google Patents
Υγρη συνταγοποιηση που περιεχει υψηλη συγκεντρωση αντισωματοςInfo
- Publication number
- CY1113616T1 CY1113616T1 CY20121101082T CY121101082T CY1113616T1 CY 1113616 T1 CY1113616 T1 CY 1113616T1 CY 20121101082 T CY20121101082 T CY 20121101082T CY 121101082 T CY121101082 T CY 121101082T CY 1113616 T1 CY1113616 T1 CY 1113616T1
- Authority
- CY
- Cyprus
- Prior art keywords
- coclusion
- liquid
- high concentration
- containing high
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Analytical Chemistry (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Το πρόβλημα που θα επιλυθεί είναι να παρέχεται μια συνταγοποίηση που περιέχει αντίσωμα, η οποία είναι σταθερή και κατάλληλη για υποδόρια χορήγηση, όπου ο διμερισμός και η αποαμίδωση αποτρέπεται κατά τη διάρκεια μακροχρόνιας αποθήκευσης. Η παρούσα δήλωση κατευθύνεται σε μία σταθερή υγρή συνταγοποίηση που περιέχει αντίσωμα που χαρακτηρίζεται από το ότι περιέχει αργινίνη και μεθειονίνη.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2007336310 | 2007-12-27 | ||
EP08866971.8A EP2238985B2 (en) | 2007-12-27 | 2008-12-26 | High concentration antibody-containing liquid formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1113616T1 true CY1113616T1 (el) | 2016-06-22 |
Family
ID=40824372
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20121101082T CY1113616T1 (el) | 2007-12-27 | 2012-11-13 | Υγρη συνταγοποιηση που περιεχει υψηλη συγκεντρωση αντισωματος |
Country Status (31)
Country | Link |
---|---|
US (8) | US8568720B2 (el) |
EP (1) | EP2238985B2 (el) |
JP (7) | JP4937358B2 (el) |
KR (1) | KR101083616B1 (el) |
CN (2) | CN101883588B (el) |
AR (2) | AR069969A1 (el) |
AU (1) | AU2008344292B2 (el) |
BR (1) | BRPI0818903B8 (el) |
CA (1) | CA2708627C (el) |
CL (1) | CL2008003910A1 (el) |
CO (1) | CO6450630A2 (el) |
CR (1) | CR11594A (el) |
CY (1) | CY1113616T1 (el) |
DK (1) | DK2238985T4 (el) |
EC (1) | ECSP10010370A (el) |
ES (1) | ES2389881T5 (el) |
HR (1) | HRP20120903T4 (el) |
IL (2) | IL206548A (el) |
MA (1) | MA31934B1 (el) |
MX (1) | MX2010004399A (el) |
MY (1) | MY159450A (el) |
NZ (1) | NZ586378A (el) |
PE (1) | PE20091174A1 (el) |
PL (1) | PL2238985T5 (el) |
PT (1) | PT2238985E (el) |
RU (2) | RU2497544C2 (el) |
SG (1) | SG2013049325A (el) |
SI (1) | SI2238985T2 (el) |
TW (1) | TWI375566B (el) |
UA (1) | UA104134C2 (el) |
WO (1) | WO2009084659A1 (el) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69839992D1 (de) | 1997-03-21 | 2008-10-23 | Chugai Pharmaceutical Co Ltd | Vorbeugende- oder Heilmittel zur Behandlung von Multipler Sklerose, mit antagonistischen anti-IL6-Rezeptor Antikörpern als Wirkstoff |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
EP3192528A1 (en) | 2002-02-14 | 2017-07-19 | Chugai Seiyaku Kabushiki Kaisha | Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer |
GB2401040A (en) * | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
US8398980B2 (en) | 2004-03-24 | 2013-03-19 | Chugai Seiyaku Kabushiki Kaisha | Subtypes of humanized antibody against interleuken-6 receptor |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
JP5620626B2 (ja) | 2005-03-31 | 2014-11-05 | 中外製薬株式会社 | 会合制御によるポリペプチド製造方法 |
EP1977763A4 (en) * | 2005-12-28 | 2010-06-02 | Chugai Pharmaceutical Co Ltd | STABILIZER PREPARATION CONTAINING ANTIBODIES |
US9670269B2 (en) | 2006-03-31 | 2017-06-06 | Chugai Seiyaku Kabushiki Kaisha | Methods of modifying antibodies for purification of bispecific antibodies |
EP4001409A1 (en) | 2006-03-31 | 2022-05-25 | Chugai Seiyaku Kabushiki Kaisha | Methods for controlling blood pharmacokinetics of antibodies |
DK2202245T3 (en) | 2007-09-26 | 2016-11-21 | Chugai Pharmaceutical Co Ltd | A method of modifying an antibody isoelectric point VIA amino acid substitution in CDR |
PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
AU2010311567B2 (en) | 2009-10-26 | 2015-03-26 | Chugai Seiyaku Kabushiki Kaisha | Method for the production of a glycosylated immunoglobulin |
AU2013202276B2 (en) * | 2009-12-21 | 2016-03-24 | Genentech, Inc. | Antibody formulation |
TWI623323B (zh) * | 2009-12-21 | 2018-05-11 | 建南德克公司 | 抗體調配物 |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
EA034617B1 (ru) * | 2010-10-06 | 2020-02-27 | Ридженерон Фармасьютикалз, Инк. | Дозированная форма жидкой фармацевтической композиции, содержащей антитела к рецептору интерлейкина-4 (il-4r) |
RU2013126477A (ru) | 2010-11-08 | 2014-12-20 | Дженентек, Инк. | Вводимые подкожно антитела против рецептора il-6 |
US9334331B2 (en) | 2010-11-17 | 2016-05-10 | Chugai Seiyaku Kabushiki Kaisha | Bispecific antibodies |
EP2508525A1 (en) | 2011-04-05 | 2012-10-10 | Bayer Pharma Aktiengesellschaft | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline salts |
SG193963A1 (en) * | 2011-04-07 | 2013-11-29 | Glaxosmithkline Llc | Formulations with reduced viscosity |
JP2014510152A (ja) * | 2011-04-07 | 2014-04-24 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 粘度が低減された処方物 |
UY34105A (es) * | 2011-06-03 | 2012-07-31 | Lg Life Sciences Ltd | Formulación líquida estable de etanercept |
WO2013012022A1 (ja) | 2011-07-19 | 2013-01-24 | 中外製薬株式会社 | アルギニンアミドまたはその類似化合物を含む安定なタンパク質含有製剤 |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
EP2750784A1 (en) | 2011-09-01 | 2014-07-09 | Chugai Seiyaku Kabushiki Kaisha | Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration |
CN104023743B (zh) | 2011-10-25 | 2017-05-03 | 普罗西纳治疗有限公司 | 抗体制剂和方法 |
CA2951856A1 (en) | 2011-10-28 | 2013-05-02 | Integritybio Inc. | Protein formulations containing amino acids |
WO2013164837A1 (en) | 2012-03-07 | 2013-11-07 | Cadila Healthcare Limited | Pharmaceutical formulations of tnf-alpha antibodies |
CA2873646C (en) | 2012-05-18 | 2022-04-26 | Genentech, Inc. | High-concentration monoclonal antibody formulations |
EP2873422A4 (en) * | 2012-07-10 | 2015-12-30 | Takeda Pharmaceutical | PHARMACEUTICAL PREPARATION FOR INJECTION |
US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
KR102362829B1 (ko) * | 2012-09-07 | 2022-02-15 | 코히러스 바이오사이언시즈, 인코포레이티드 | 아달리무맙의 안정한 수성 제형 |
CN104870474B (zh) | 2012-10-04 | 2019-03-12 | 诺沃姆德治疗公司 | 用于治疗溶血性疾病的旁路途径特异性抗体 |
EP2911693A4 (en) * | 2012-10-25 | 2016-04-27 | Medimmune Llc | STABLE, LOW-VISIC ANTIBODY FORMULATION |
MX363403B (es) | 2013-07-04 | 2019-03-22 | Hoffmann La Roche | Inmumoensayo con interferencia suprimida para la deteccion de anticuerpos anti-farmacos en muestras de suero. |
KR20240042200A (ko) | 2013-09-11 | 2024-04-01 | 이글 바이오로직스 인코퍼레이티드 | 점도저하제를 함유하는 액체 단백질 제형 |
RU2758952C1 (ru) | 2013-09-27 | 2021-11-03 | Чугаи Сейяку Кабусики Кайся | Способ получения полипептидного гетеромультимера |
TWI694836B (zh) * | 2014-05-16 | 2020-06-01 | 英商葛蘭素史克智慧財產管理有限公司 | 抗體調配物 |
US20160074515A1 (en) | 2014-06-20 | 2016-03-17 | Reform Biologics, Llc | Viscosity-reducing excipient compounds for protein formulations |
US11357857B2 (en) | 2014-06-20 | 2022-06-14 | Comera Life Sciences, Inc. | Excipient compounds for protein processing |
US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
BR112017004393A2 (pt) | 2014-09-15 | 2018-02-27 | Genentech Inc | formulações de anticorpo |
TWI701435B (zh) | 2014-09-26 | 2020-08-11 | 日商中外製藥股份有限公司 | 測定fviii的反應性之方法 |
TWI700300B (zh) | 2014-09-26 | 2020-08-01 | 日商中外製藥股份有限公司 | 中和具有第viii凝血因子(fviii)機能替代活性的物質之抗體 |
KR102497368B1 (ko) | 2014-10-01 | 2023-02-10 | 이글 바이올로직스 인코포레이티드 | 점도-저하제를 함유하는 폴리삭카라이드 및 핵산 제형 |
WO2016085787A1 (en) | 2014-11-25 | 2016-06-02 | Corning Incorporated | Cell culture media extending materials and methods |
AR103173A1 (es) * | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
JP2018500380A (ja) * | 2014-12-31 | 2018-01-11 | ノベルメド セラピューティクス,インコーポレーテッド | アグリコシル化治療用抗体の製剤 |
JP6731953B2 (ja) * | 2015-02-11 | 2020-07-29 | ジーエムエーエックス バイオファーム エルエルシー. | Glp−1r抗体融合タンパク質の安定な医薬溶液製剤 |
AR103726A1 (es) | 2015-02-27 | 2017-05-31 | Merck Sharp & Dohme | Cristales de anticuerpos monoclonales anti-pd-1 humanos |
JP7082484B2 (ja) | 2015-04-01 | 2022-06-08 | 中外製薬株式会社 | ポリペプチド異種多量体の製造方法 |
KR20180034672A (ko) | 2015-08-18 | 2018-04-04 | 리제너론 파아마슈티컬스, 인크. | 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체 |
TW201726111A (zh) * | 2015-09-30 | 2017-08-01 | 持田製藥股份有限公司 | 含高濃度抗體之液體製劑 |
US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
SG11201805123XA (en) * | 2015-12-18 | 2018-07-30 | Astellas Pharma Inc | Pharmaceutical composition comprising anti-human tslp receptor antibody |
KR20180091918A (ko) | 2015-12-28 | 2018-08-16 | 추가이 세이야쿠 가부시키가이샤 | Fc 영역 함유 폴리펩타이드의 정제를 효율화하기 위한 방법 |
US11484591B2 (en) | 2016-02-22 | 2022-11-01 | Ohio State Innovation Foundation | Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites |
US20170240617A1 (en) * | 2016-02-24 | 2017-08-24 | Visterra, Inc. | Formulations of antibody molecules to influenza virus |
WO2017184880A1 (en) | 2016-04-20 | 2017-10-26 | Coherus Biosciences, Inc. | A method of filling a container with no headspace |
EP3449940A4 (en) * | 2016-04-28 | 2020-01-22 | Chugai Seiyaku Kabushiki Kaisha | ANTIBODY PREPARATION |
TWI826351B (zh) * | 2016-05-31 | 2023-12-21 | 大陸商鴻運華寧(杭州)生物醫藥有限公司 | R抗體,其藥物組合物及其應用 |
KR20220137159A (ko) * | 2016-07-05 | 2022-10-11 | 사노피 | 항체 제형 |
MX2019002510A (es) | 2016-09-06 | 2019-06-24 | Chugai Pharmaceutical Co Ltd | Metodos para usar un anticuerpo biespecifico que reconoce el factor de coagulacion ix y/o el factor de coagulacion ix activado y el factor de coagulacion x y/o factor de coagulacion x activado. |
CN109862880A (zh) | 2016-09-27 | 2019-06-07 | 德国费森尤斯卡比有限公司 | 液体药物组合物 |
ES2882181T3 (es) | 2016-10-31 | 2021-12-01 | Fresenius Kabi Deutschland Gmbh | Composición farmacéutica líquida |
WO2018116198A1 (en) | 2016-12-23 | 2018-06-28 | Serum Institute Of India Private Limited | Improved methods for enhancing antibody productivity in mammalian cell culture and minimizing aggregation during downstream, formulation processes and stable antibody formulations obtained thereof |
EP3576790A4 (en) | 2017-02-01 | 2020-12-23 | Yale University | TREATMENT OF DIURETIC RESISTANCE |
GB201703063D0 (en) | 2017-02-24 | 2017-04-12 | Arecor Ltd | Stabilized antibody protein solutions |
US11608357B2 (en) | 2018-08-28 | 2023-03-21 | Arecor Limited | Stabilized antibody protein solutions |
TWI761453B (zh) * | 2017-03-01 | 2022-04-21 | 英商梅迪繆思有限公司 | 抗rsv單株抗體配製物 |
EP3372242A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
EP3372241A1 (en) | 2017-03-06 | 2018-09-12 | Ares Trading S.A. | Liquid pharmaceutical composition |
CN110603057A (zh) | 2017-03-17 | 2019-12-20 | 俄亥俄州创新基金会 | 用于递送化学预防剂的纳米颗粒 |
WO2018179138A1 (ja) * | 2017-03-29 | 2018-10-04 | 持田製薬株式会社 | 抗体含有液体製剤 |
KR20190129061A (ko) | 2017-03-31 | 2019-11-19 | 메이지 세이카 파루마 가부시키가이샤 | 수성 제제 및 주사기 내 수성 제제, 및 항체 단백질 탈응집제 및 항체 단백질 탈응집 방법 |
RU2019138507A (ru) * | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
EP3624846A1 (en) | 2017-05-16 | 2020-03-25 | Bhami's Research Laboratory, Pvt. Ltd. | High concentration protein formulations with reduced viscosity |
CA3073066A1 (en) * | 2017-08-22 | 2019-02-28 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-beta amyloid antibodies |
BR112020003498A2 (pt) * | 2017-08-22 | 2020-08-25 | Biogen Ma, Inc. | composições farmacêuticas e regimes de dosagem que contêm anticorpos anti-alfa(v)beta(6) |
CR20210381A (es) | 2017-09-29 | 2021-09-09 | Chugai Pharmaceutical Co Ltd | MOLÉCULA DE UNIÓN AL ANTÍGENO MULTIESPECÍFICA QUE TIENE ACTIVIDAD DE SUSTITUCIÓN DE LA FUNCIÓN DE COFACTOR DEL FACTOR VIII DE COAGULACIÓN DE SANGRE (FVIII) Y FORMULACIÓN FARMACÉUTICA QUE CONTIENE TAL MOLÉCULA COMO INGREDIENTE (Divisional Exp. 2020-0158) |
CA3087699A1 (en) | 2018-01-05 | 2019-07-11 | Corvidia Therapeutics, Inc. | Methods for treating il-6 mediated inflammation without immunosuppression |
WO2019217927A1 (en) | 2018-05-10 | 2019-11-14 | Regeneron Pharmaceuticals, Inc. | High concentration vegf receptor fusion protein containing formulations |
EP3849615A1 (en) | 2018-09-12 | 2021-07-21 | Silverback Therapeutics, Inc. | Compositions for the treatment of disease with immune stimulatory conjugates |
WO2020185750A1 (en) * | 2019-03-11 | 2020-09-17 | Biogen Ma Inc. | Pharmaceutical compositions containing anti-lingo-1 antibodies |
WO2020201362A2 (en) | 2019-04-02 | 2020-10-08 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of predicting and preventing cancer in patients having premalignant lesions |
US20200347120A1 (en) * | 2019-04-30 | 2020-11-05 | Medimmune Limited | Dosage regimens for and compositions including anti-rsv antibodies |
KR102169901B1 (ko) * | 2019-05-17 | 2020-10-26 | 연세대학교 산학협력단 | Dna 메틸화를 이용한 면역 항암 요법의 치료 반응에 관한 정보 제공 방법 및 이를 이용한 키트 |
BR112021025699A2 (pt) | 2019-06-19 | 2022-03-03 | Silverback Therapeutics Inc | Anticorpos anti-mesotelina e imunoconjugados dos mesmos |
CN112618482A (zh) * | 2019-09-24 | 2021-04-09 | 江苏恒瑞医药股份有限公司 | 新型蛋白制剂 |
US11179473B2 (en) | 2020-02-21 | 2021-11-23 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
JP2023518812A (ja) | 2020-03-23 | 2023-05-08 | ジェネンテック, インコーポレイテッド | Covid19肺炎を治療するための、トシリズマブとレムデシビルとの組み合わせ |
WO2021194861A1 (en) | 2020-03-23 | 2021-09-30 | Genentech, Inc. | Biomarkers for predicting response to il-6 antagonist in covid-19 pneumonia |
CN115916820A (zh) | 2020-03-23 | 2023-04-04 | 基因泰克公司 | 用il6拮抗剂治疗包括covid-19肺炎在内的肺炎的方法 |
AR122766A1 (es) * | 2020-06-29 | 2022-10-05 | Hanall Biopharma Co Ltd | Formulación para anticuerpos anti-fcrn |
IL299508A (en) | 2020-07-01 | 2023-02-01 | Ars Pharmaceuticals Inc | Name of the invention: antibody conjugates against ASGR1 and their uses |
KR20220028972A (ko) * | 2020-08-31 | 2022-03-08 | (주)셀트리온 | 안정한 약제학적 제제 |
JP2023541921A (ja) | 2020-09-17 | 2023-10-04 | ジェネンテック, インコーポレイテッド | Covid-19肺炎を有する入院患者におけるトシリズマブの有効性及び安全性を評価するためのランダム化二重盲検プラセボ対照多施設試験(empacta)の結果 |
WO2022098750A1 (en) * | 2020-11-03 | 2022-05-12 | La Jolla Institute For Immunology | Hla class ii-restricted tcrs against the kras g12>v activating mutation |
WO2024090488A1 (ja) * | 2022-10-26 | 2024-05-02 | 日本メジフィジックス株式会社 | 放射性医薬組成物 |
Family Cites Families (125)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS55106216A (en) | 1979-02-09 | 1980-08-14 | Hitachi Chem Co Ltd | Preparation of amino resin |
JPS58201994A (ja) | 1982-05-21 | 1983-11-25 | Hideaki Hagiwara | 抗原特異的ヒト免疫グロブリンの生産方法 |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
JPS63453A (ja) | 1986-06-20 | 1988-01-05 | Tohoku Metal Ind Ltd | 耐酸化性永久磁石材料とその製造方法 |
US5670373A (en) | 1988-01-22 | 1997-09-23 | Kishimoto; Tadamitsu | Antibody to human interleukin-6 receptor |
US5171840A (en) | 1988-01-22 | 1992-12-15 | Tadamitsu Kishimoto | Receptor protein for human B cell stimulatory factor-2 |
US6428979B1 (en) | 1988-01-22 | 2002-08-06 | Tadamitsu Kishimoto | Receptor protein for human B cell stimulatory factor-2 |
US5158761A (en) * | 1989-04-05 | 1992-10-27 | Toko Yakuhin Kogyo Kabushiki Kaisha | Spray gel base and spray gel preparation using thereof |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DK0585287T3 (da) | 1990-07-10 | 2000-04-17 | Cambridge Antibody Tech | Fremgangsmåde til fremstilling af specifikke bindingsparelementer |
WO1993012227A1 (en) | 1991-12-17 | 1993-06-24 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
DK0546073T3 (da) | 1990-08-29 | 1998-02-02 | Genpharm Int | Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer |
RU2139351C1 (ru) | 1991-04-25 | 1999-10-10 | Чугаи Сейяку Кабусики Кайся | Н- и l-цепи моноклонального антитела рм1 (монат) к рецептору il-6r человека и их v-области, модифицированная монат, его н- и l-цепи и их v-области, cdr- последовательности, днк-последовательности |
EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
WO1993011236A1 (en) | 1991-12-02 | 1993-06-10 | Medical Research Council | Production of anti-self antibodies from antibody segment repertoires and displayed on phage |
EP0656941B1 (en) | 1992-03-24 | 2005-06-01 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
WO1994002602A1 (en) | 1992-07-24 | 1994-02-03 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
AU6819494A (en) | 1993-04-26 | 1994-11-21 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
GB9313509D0 (en) | 1993-06-30 | 1993-08-11 | Medical Res Council | Chemisynthetic libraries |
US5888510A (en) | 1993-07-21 | 1999-03-30 | Chugai Seiyaku Kabushiki Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
EP0731842A1 (en) | 1993-12-03 | 1996-09-18 | Medical Research Council | Recombinant binding proteins and peptides |
US8017121B2 (en) | 1994-06-30 | 2011-09-13 | Chugai Seiyaku Kabushika Kaisha | Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component |
WO1996002576A1 (fr) | 1994-07-13 | 1996-02-01 | Chugai Seiyaku Kabushiki Kaisha | Anticorps humain reconstitue contre l'interleukine-8 humaine |
JP3630453B2 (ja) | 1994-09-30 | 2005-03-16 | 中外製薬株式会社 | Il−6レセプター抗体を有効成分とする未熟型骨髄腫細胞治療剤 |
EP0791359A4 (en) | 1994-10-21 | 2002-09-11 | Chugai Pharmaceutical Co Ltd | MEDICINE AGAINST IL-6 PRODUCTION IN DISEASES |
JP4079461B2 (ja) | 1994-12-29 | 2008-04-23 | 中外製薬株式会社 | Il−6アンタゴニストを含んでなる抗腫瘍剤の作用増強剤 |
ES2264135T3 (es) | 1995-02-13 | 2006-12-16 | Chugai Seiyaku Kabushiki Kaisha | Inhibidor de la descomposicion de proteinas musculares que contienen anticuerpos frente al receptor de il-6. |
DE69637481T2 (de) | 1995-04-27 | 2009-04-09 | Amgen Fremont Inc. | Aus immunisierten Xenomäusen stammende menschliche Antikörper gegen IL-8 |
AU2466895A (en) | 1995-04-28 | 1996-11-18 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
ATE326238T1 (de) | 1996-06-27 | 2006-06-15 | Chugai Pharmaceutical Co Ltd | Mittel gegen myelome, welches zusammen mit antitumorwirkstoffen auf der basis von stickstoff-senfgasen verwendet werden kann |
CZ106299A3 (cs) | 1996-09-26 | 1999-08-11 | Chugai Seiyaku Kabushiki Kaisha | Protilátky proti proteinu příbuznému s lidským parathyroidálním hormonem |
UA76934C2 (en) | 1996-10-04 | 2006-10-16 | Chugai Pharmaceutical Co Ltd | Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody |
DE69839992D1 (de) | 1997-03-21 | 2008-10-23 | Chugai Pharmaceutical Co Ltd | Vorbeugende- oder Heilmittel zur Behandlung von Multipler Sklerose, mit antagonistischen anti-IL6-Rezeptor Antikörpern als Wirkstoff |
US6991790B1 (en) | 1997-06-13 | 2006-01-31 | Genentech, Inc. | Antibody formulation |
US20020187150A1 (en) | 1997-08-15 | 2002-12-12 | Chugai Seiyaku Kabushiki Kaisha | Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient |
PL201461B1 (pl) | 1998-03-17 | 2009-04-30 | Chugai Pharmaceutical Co Ltd | Czynnik zapobiegający lub terapeutyczny do leczenia zapalenia jelita, zawierający antagonistę IL-6 jako składnik aktywny |
CA2325346A1 (en) | 1998-04-03 | 1999-10-14 | Chugai Seiyaku Kabushiki Kaisha | Humanized antibody against human tissue factor (tf) and process for constructing humanized antibody |
US6537782B1 (en) | 1998-06-01 | 2003-03-25 | Chugai Seiyaku Kabushiki Kaisha | Media for culturing animal cells and process for producing protein by using the same |
US6406909B1 (en) | 1998-07-10 | 2002-06-18 | Chugai Seiyaku Kabushiki Kaisha | Serum-free medium for culturing animal cells |
ATE350060T1 (de) | 1998-08-24 | 2007-01-15 | Chugai Pharmaceutical Co Ltd | Mittel zur vorbeugung oder behandlung von pankreatitis die anti-il-6 receptor antikörper als aktive komponente enthalten |
JP2000247903A (ja) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
JP2007204498A (ja) * | 1999-03-01 | 2007-08-16 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
US6914128B1 (en) * | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
ES2329437T3 (es) * | 1999-06-25 | 2009-11-26 | Genentech, Inc. | Anticuerpos anti-erbb2 humanizados y tratamiento con anticuerpos anti-erbb2. |
PL211886B1 (pl) | 1999-10-04 | 2012-07-31 | Novartis Vaccines & Diagnostic | Stabilizowana ciekła kompozycja farmaceutyczna, sposób zwiększania trwałości polipeptydu, sposób zwiększania trwałości podczas przechowywania kompozycji, sucha postać kompozycji oraz preparat zawierający kompozycję |
EP1260230A4 (en) | 2000-02-29 | 2008-08-06 | Chugai Pharmaceutical Co Ltd | LONG-TERM STABILIZED PREPARATIONS |
TWI241345B (en) | 2000-03-10 | 2005-10-11 | Chugai Pharmaceutical Co Ltd | Apoptosis inducing polypeptide |
JP4812228B2 (ja) | 2000-08-10 | 2011-11-09 | 中外製薬株式会社 | 抗体含有溶液の凝集物生成または白濁抑制方法 |
ES2644275T3 (es) * | 2000-08-11 | 2017-11-28 | Chugai Seiyaku Kabushiki Kaisha | Preparaciones estabilizadas que contienen anticuerpos |
EP1930024A3 (en) | 2000-09-01 | 2008-08-06 | Chugai Seiyaku Kabushiki Kaisha | G-CSF solution formulations having long-term stability |
DK1324776T4 (en) * | 2000-10-12 | 2018-05-28 | Genentech Inc | CONCENTRATED PROTEIN FORMULATIONS WITH REDUCED VISCOSITY |
US8703126B2 (en) | 2000-10-12 | 2014-04-22 | Genentech, Inc. | Reduced-viscosity concentrated protein formulations |
AU2002210917B2 (en) | 2000-10-20 | 2006-05-18 | Chugai Seiyaku Kabushiki Kaisha | Degraded TPO agonist antibody |
EP1334731B1 (en) | 2000-10-25 | 2008-02-27 | Chugai Seiyaku Kabushiki Kaisha | Preventives or remedies for psoriasis containing as the active ingredient il-6 antagonist |
JP4889187B2 (ja) | 2000-10-27 | 2012-03-07 | 中外製薬株式会社 | Il−6アンタゴニストを有効成分として含有する血中mmp−3濃度低下剤 |
AU2000279624A1 (en) | 2000-10-27 | 2002-05-15 | Chugai Seiyaku Kabushiki Kaisha | Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient |
WO2002072615A1 (fr) | 2001-03-09 | 2002-09-19 | Chugai Seiyaku Kabushiki Kaisha | Methode de purification de proteines |
UA80091C2 (en) | 2001-04-02 | 2007-08-27 | Chugai Pharmaceutical Co Ltd | Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist |
ATE556591T1 (de) | 2001-11-08 | 2012-05-15 | Abbott Biotherapeutics Corp | Stabile pharmazeutische flüssigformulierung von igg-antikörpern |
KR20100120246A (ko) | 2001-11-14 | 2010-11-12 | 센토코 오르토 바이오테크 인코포레이티드 | 항 il-6 항체, 조성물, 방법 및 용도 |
US20030138416A1 (en) * | 2001-12-03 | 2003-07-24 | Jesper Lau | Use of glucokinase activator in combination with a glucagon antagonist for treating type 2 diabetes |
EP3192528A1 (en) | 2002-02-14 | 2017-07-19 | Chugai Seiyaku Kabushiki Kaisha | Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer |
PL215168B1 (pl) | 2002-02-27 | 2013-10-31 | Immunex Corp | Formulacja polipeptydowa |
JP3822137B2 (ja) | 2002-05-20 | 2006-09-13 | 中外製薬株式会社 | 動物細胞培養用培地の添加剤およびそれを用いたタンパク質の製造方法 |
MXPA05002219A (es) | 2002-08-28 | 2005-07-05 | Immunex Corp | Composiciones y metodos para tratar una enfermedad cardiovascular. |
SI2261230T1 (sl) | 2002-09-11 | 2017-08-31 | Chugai Seiyaku Kabushiki Kaisha | Postopek čiščenja proteinov |
DE10255508A1 (de) | 2002-11-27 | 2004-06-17 | Forschungszentrum Jülich GmbH | Verfahren zur Kultivierung von Zellen zur Produktion von Substanzen |
WO2004055164A2 (en) * | 2002-12-13 | 2004-07-01 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
EP1607100A4 (en) | 2003-02-24 | 2007-06-13 | Chugai Pharmaceutical Co Ltd | MEDICAMENT WITH AN INTERLEUKIN-6 ANTAGONIST FOR BACK-MARGIN INJURIES |
US20050158303A1 (en) | 2003-04-04 | 2005-07-21 | Genentech, Inc. | Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations |
LT2335725T (lt) | 2003-04-04 | 2017-01-25 | Genentech, Inc. | Didelės koncentracijos antikūno ir baltymo kompozicijos |
GB2401040A (en) | 2003-04-28 | 2004-11-03 | Chugai Pharmaceutical Co Ltd | Method for treating interleukin-6 related diseases |
JP5452835B2 (ja) | 2003-07-15 | 2014-03-26 | 中外製薬株式会社 | 形質転換細胞によるIgMの産生とその定量方法 |
NZ546557A (en) | 2003-10-17 | 2010-01-29 | Chugai Pharmaceutical Co Ltd | Therapeutic agent for mesothelioma comprising interleukin-6 |
EP1532983A1 (en) * | 2003-11-18 | 2005-05-25 | ZLB Bioplasma AG | Immunoglobulin preparations having increased stability |
DE10355251A1 (de) * | 2003-11-26 | 2005-06-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor |
AR048210A1 (es) | 2003-12-19 | 2006-04-12 | Chugai Pharmaceutical Co Ltd | Un agente preventivo para la vasculitis. |
US8617550B2 (en) | 2003-12-19 | 2013-12-31 | Chugai Seiyaku Kabushiki Kaisha | Treatment of vasculitis with IL-6 antagonist |
US20070184050A1 (en) | 2003-12-25 | 2007-08-09 | Kirin Beer Kabushiki Kaisha | Stable water-based medicinal preparation containing antibody |
CN1953768B (zh) * | 2004-02-12 | 2010-10-13 | 默克专利有限公司 | 抗-egfr抗体的高浓缩液体制剂 |
WO2005089503A2 (en) * | 2004-03-19 | 2005-09-29 | Progenics Pharmaceuticals, Inc. | Cd4-igg2 formulations |
AR048335A1 (es) | 2004-03-24 | 2006-04-19 | Chugai Pharmaceutical Co Ltd | Agentes terapeuticos para trastornos del oido interno que contienen un antagonista de il- 6 como un ingrediente activo |
US8398980B2 (en) | 2004-03-24 | 2013-03-19 | Chugai Seiyaku Kabushiki Kaisha | Subtypes of humanized antibody against interleuken-6 receptor |
SI1778723T1 (sl) * | 2004-08-17 | 2013-02-28 | Regeneron Pharmaceuticals, Inc. | Formulacije IL-1 antagonista |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
EP2843040A1 (en) | 2005-01-05 | 2015-03-04 | Chugai Seiyaku Kabushiki Kaisha | Cell culture method and utilization of the same |
JP2008528638A (ja) * | 2005-01-28 | 2008-07-31 | ワイス | ポリペプチドの安定化液体処方 |
NZ623901A (en) | 2005-08-03 | 2015-10-30 | Immunogen Inc | Immunoconjugate formulations |
AU2006300234B2 (en) | 2005-10-14 | 2013-01-10 | Chugai Seiyaku Kabushiki Kaisha | Agents for suppressing damage to transplanted islets after islet transplantation |
KR101239051B1 (ko) | 2005-10-21 | 2013-03-04 | 추가이 세이야쿠 가부시키가이샤 | 심장질환 치료제 |
AR057582A1 (es) | 2005-11-15 | 2007-12-05 | Nat Hospital Organization | Agentes para suprimir la induccion de linfocitos t citotoxicos |
TW200803894A (en) | 2005-11-25 | 2008-01-16 | Univ Keio | Prostate cancer therapeutic agents |
EP1977763A4 (en) * | 2005-12-28 | 2010-06-02 | Chugai Pharmaceutical Co Ltd | STABILIZER PREPARATION CONTAINING ANTIBODIES |
CN104189907A (zh) | 2006-01-27 | 2014-12-10 | 学校法人庆应义塾 | 伴有脉络膜血管生成的疾病的治疗药 |
EP1988922A4 (en) * | 2006-02-03 | 2010-06-02 | Medimmune Llc | PROTEIN FORMULATIONS |
JP4902674B2 (ja) | 2006-03-09 | 2012-03-21 | エフ.ホフマン−ラ ロシュ アーゲー | 抗薬物抗体アッセイ法 |
TW200806317A (en) | 2006-03-20 | 2008-02-01 | Wyeth Corp | Methods for reducing protein aggregation |
EP2025346B1 (en) | 2006-04-07 | 2016-08-10 | Osaka University | Muscle regeneration promoter |
NZ571757A (en) | 2006-04-21 | 2012-01-12 | Novartis Ag | Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer |
WO2008016134A1 (fr) | 2006-08-04 | 2008-02-07 | Norihiro Nishimoto | PROCÉDÉ POUR PRÉDIRE LE PRONOSTIC DES PATIENTS ATTEINTS DE POLYARTHRITE rhumatoïde |
JP2010095445A (ja) | 2006-12-27 | 2010-04-30 | Tokyo Medical & Dental Univ | Il−6アンタゴニストを有効成分とする炎症性筋疾患治療剤 |
CN101600457B (zh) | 2007-01-09 | 2014-01-08 | 惠氏公司 | 抗il-13抗体调配物和其用途 |
MX2009007830A (es) | 2007-01-23 | 2009-10-07 | Univ Shinshu | Inhibidor de rechazo cronico. |
WO2009014263A1 (ja) | 2007-07-26 | 2009-01-29 | Osaka University | インターロイキン6受容体阻害剤を有効成分とする眼炎症疾患治療剤 |
BRPI0817250A2 (pt) | 2007-09-26 | 2014-06-17 | Chugai Pharmaceutical Co Ltd | Anticorpo anti-receptor da il-6. |
CN101815532B (zh) | 2007-10-02 | 2012-08-15 | 中外制药株式会社 | 以白细胞介素6受体抑制剂为有效成分的移植物抗宿主病治疗剂 |
JP2009092508A (ja) | 2007-10-09 | 2009-04-30 | Norihiro Nishimoto | リウマチ治療剤の効果の予測方法 |
US8227195B2 (en) | 2007-12-15 | 2012-07-24 | Hoffman-La Roche Inc. | Distinguishing assay |
PE20091174A1 (es) | 2007-12-27 | 2009-08-03 | Chugai Pharmaceutical Co Ltd | Formulacion liquida con contenido de alta concentracion de anticuerpo |
US10717781B2 (en) | 2008-06-05 | 2020-07-21 | National Cancer Center | Neuroinvasion inhibitor |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
US20120183539A1 (en) | 2009-07-31 | 2012-07-19 | Shin Maeda | Cancer Metastasis Inhibitor |
AU2010311567B2 (en) | 2009-10-26 | 2015-03-26 | Chugai Seiyaku Kabushiki Kaisha | Method for the production of a glycosylated immunoglobulin |
TWI505838B (zh) † | 2010-01-20 | 2015-11-01 | Chugai Pharmaceutical Co Ltd | Stabilized antibody solution containing |
WO2011128096A1 (en) | 2010-04-16 | 2011-10-20 | Roche Diagnostics Gmbh | Polymorphism markers for predicting response to interleukin-6 receptor-inhibiting monoclonal antibody drug treatment |
ES2932398T3 (es) | 2010-05-28 | 2023-01-18 | Chugai Pharmaceutical Co Ltd | Potenciador de la respuesta de las células T antitumorales |
US20130149302A1 (en) | 2010-05-28 | 2013-06-13 | Chugai Seiyaku Kabushiki Kaisha | Therapeutic agents for pancreatic cancer |
CN103119176A (zh) | 2010-06-07 | 2013-05-22 | 霍夫曼-拉罗奇有限公司 | 用于预测对白介素-6受体抑制性单克隆抗体药物治疗的响应的基因表达标记 |
RU2013126477A (ru) | 2010-11-08 | 2014-12-20 | Дженентек, Инк. | Вводимые подкожно антитела против рецептора il-6 |
EP2750784A1 (en) | 2011-09-01 | 2014-07-09 | Chugai Seiyaku Kabushiki Kaisha | Method for preparing a composition comprising highly concentrated antibodies by ultrafiltration |
MX363403B (es) | 2013-07-04 | 2019-03-22 | Hoffmann La Roche | Inmumoensayo con interferencia suprimida para la deteccion de anticuerpos anti-farmacos en muestras de suero. |
US10349940B2 (en) | 2015-08-24 | 2019-07-16 | Ethicon Llc | Surgical stapler buttress applicator with state indicator |
CN109862880A (zh) | 2016-09-27 | 2019-06-07 | 德国费森尤斯卡比有限公司 | 液体药物组合物 |
ES2882181T3 (es) | 2016-10-31 | 2021-12-01 | Fresenius Kabi Deutschland Gmbh | Composición farmacéutica líquida |
US20220071901A1 (en) | 2017-11-30 | 2022-03-10 | Bio-Thera Solutions, Ltd. | A liquid formulation of humanized antibody for treating il-6-mediated diseases |
-
2008
- 2008-12-22 PE PE2008002174A patent/PE20091174A1/es active IP Right Grant
- 2008-12-23 AR ARP080105706A patent/AR069969A1/es not_active Application Discontinuation
- 2008-12-26 BR BRPI0818903A patent/BRPI0818903B8/pt active IP Right Grant
- 2008-12-26 JP JP2009548102A patent/JP4937358B2/ja active Active
- 2008-12-26 TW TW097151029A patent/TWI375566B/zh active
- 2008-12-26 SI SI200830806T patent/SI2238985T2/sl unknown
- 2008-12-26 WO PCT/JP2008/073798 patent/WO2009084659A1/ja active Application Filing
- 2008-12-26 UA UAA201009396A patent/UA104134C2/ru unknown
- 2008-12-26 CL CL2008003910A patent/CL2008003910A1/es unknown
- 2008-12-26 AU AU2008344292A patent/AU2008344292B2/en active Active
- 2008-12-26 CA CA2708627A patent/CA2708627C/en active Active
- 2008-12-26 US US12/810,938 patent/US8568720B2/en active Active
- 2008-12-26 EP EP08866971.8A patent/EP2238985B2/en active Active
- 2008-12-26 CN CN200880119066.5A patent/CN101883588B/zh active Active
- 2008-12-26 DK DK08866971.8T patent/DK2238985T4/da active
- 2008-12-26 RU RU2010131179/15A patent/RU2497544C2/ru active
- 2008-12-26 PT PT08866971T patent/PT2238985E/pt unknown
- 2008-12-26 KR KR1020107016322A patent/KR101083616B1/ko active IP Right Grant
- 2008-12-26 MX MX2010004399A patent/MX2010004399A/es active IP Right Grant
- 2008-12-26 MY MYPI2010003035A patent/MY159450A/en unknown
- 2008-12-26 PL PL08866971.8T patent/PL2238985T5/pl unknown
- 2008-12-26 NZ NZ586378A patent/NZ586378A/en unknown
- 2008-12-26 SG SG2013049325A patent/SG2013049325A/en unknown
- 2008-12-26 CN CN201610505769.8A patent/CN106075434B/zh active Active
- 2008-12-26 ES ES08866971T patent/ES2389881T5/es active Active
-
2010
- 2010-06-22 IL IL206548A patent/IL206548A/en active Protection Beyond IP Right Term
- 2010-06-25 MA MA32948A patent/MA31934B1/fr unknown
- 2010-07-26 CR CR11594A patent/CR11594A/es unknown
- 2010-07-27 CO CO10091445A patent/CO6450630A2/es not_active Application Discontinuation
- 2010-07-27 EC EC2010010370A patent/ECSP10010370A/es unknown
-
2011
- 2011-11-25 JP JP2011257255A patent/JP5906067B2/ja active Active
-
2012
- 2012-11-09 HR HRP20120903TT patent/HRP20120903T4/hr unknown
- 2012-11-13 CY CY20121101082T patent/CY1113616T1/el unknown
-
2013
- 2013-08-12 RU RU2013137740A patent/RU2701181C2/ru active
- 2013-09-03 US US14/017,013 patent/US20140005367A1/en not_active Abandoned
-
2015
- 2015-05-19 IL IL238896A patent/IL238896A/en active IP Right Grant
- 2015-11-13 JP JP2015223070A patent/JP6259436B2/ja active Active
- 2015-12-09 US US14/963,414 patent/US20160090419A1/en not_active Abandoned
-
2017
- 2017-12-07 JP JP2017234971A patent/JP6567024B2/ja active Active
-
2019
- 2019-04-22 US US16/390,197 patent/US11008394B2/en active Active
- 2019-07-30 JP JP2019139465A patent/JP2019206559A/ja active Pending
-
2020
- 2020-09-30 AR ARP200102716A patent/AR122312A2/es unknown
-
2021
- 2021-04-27 US US17/242,199 patent/US11359026B2/en active Active
- 2021-07-01 JP JP2021109852A patent/JP7256234B2/ja active Active
-
2022
- 2022-05-25 US US17/752,978 patent/US11584798B2/en active Active
-
2023
- 2023-01-25 JP JP2023009289A patent/JP2023055780A/ja active Pending
- 2023-01-31 US US18/162,368 patent/US11767363B2/en active Active
- 2023-06-15 US US18/335,789 patent/US20230340134A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1113616T1 (el) | Υγρη συνταγοποιηση που περιεχει υψηλη συγκεντρωση αντισωματος | |
CY1123079T1 (el) | Τροποποιημενα πολυπεπτιδια γiα ικριωματα διειδικων αντισωματων | |
CY1120407T1 (el) | Φαρμακοτεχνικες μορφες ινσουλινων μακρας-δρασεως | |
CY1122564T1 (el) | Μορια δεσμευσης μονhς αλυσιδας που περιλαμβανουν ν-τελικο αβρ | |
CY1118680T1 (el) | Φαρμακευτικη συνθεση | |
CL2011001497A1 (es) | Compuestos derivados de heterociclos, modulador de gpr120; composicion farmaceutica; y su uso para el tratamiento de diabetes tipo i,ii y sindrome metabolico. | |
CY1119028T1 (el) | Φαρμακευτικη ουσια συλληψης αζωτου για χρηση σε μεθοδο αγωγης διαταραχης κατακρατησης αζωτου | |
EA200802184A1 (ru) | Фармацевтические композиции с ингибиторами dpp iv | |
EA201490815A1 (ru) | Составы этанерцепта, стабилизированные с помощью аминокислот | |
EA201400993A1 (ru) | Антитела против рецептора эпидермального фактора роста, активные в определенных условиях, и способы их применения | |
EA201070518A1 (ru) | Композиция по уходу за волосами | |
BR112015023796A2 (pt) | estratégias de amsotragem de câmera sempre ligada | |
EA201201081A1 (ru) | Производные гетарил[1,8]нафтиридина | |
PE20140625A1 (es) | ANTICUERPOS ANTI-CD79b E INMUNOCONJUGADOS HUMANIZADOS | |
CY1121881T1 (el) | Φαρμακοτεχνικη μορφη που περιεχει σταθερη αναλογια ινσουλινης glargine/λιξισενατιδης | |
EA201200484A1 (ru) | Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином | |
CY1115485T1 (el) | Χρησιμοποιηση αμισουλπριδης για τη θεραπεια μετεγχειρητικης ναυτιας και εμετου | |
BR112015025614A8 (pt) | meio de armazenamento legível por computador, sistema e método implementado por computador | |
AR066395A1 (es) | Reovirus que tienen secuencias modificadas | |
ES2424810R1 (es) | Sistema para identificar areas geograficas sostenibles mediante tecnicas de deteccion remota y metodo para el mismo | |
EA201590061A1 (ru) | Фармацевтическая композиция | |
BR112013018616A2 (pt) | adesivo com base em solvente contendo gluconato de clorexidina | |
CY1117674T1 (el) | Χρηση παραγωγων των orvinol και thevinol ως θεραπευτικη αγωγη στην καταχρηση αλκοολ και φαρμακων | |
CY1124070T1 (el) | Igf-1r αντισωμα και χρηση αυτου για τη διαγνωση καρκινου | |
CL2012003119A1 (es) | Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre. |